Mepolizumab

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed “best predictor” of 12-month remission in patients with severe eosinophilic asthma, according to study data.

BOSTON — Patients with obesity and asthma may see reductions in exacerbations with biologic treatment, according to a presentation at the CHEST Annual Meeting.

The FDA has accepted to review a supplemental new drug application for mepolizumab, an anti-IL-5 biologic, for treating patients with COPD plus an eosinophilic phenotype, according to a GSK press release.

BOSTON — Patients taking benralizumab experienced more asthma exacerbations than patients taking mepolizumab, according to an abstract presented at the CHEST Annual Meeting.

BOSTON — Symptoms improved with mepolizumab after treatment with omalizumab failed for a patient with asthma who developed allergic bronchopulmonary aspergillosis, according to a poster presented at the CHEST Annual Meeting.

Patients with severe asthma and small airways disease did not respond as well to omalizumab treatment, according to a poster presented at the European Respiratory Society International Congress.

Mepolizumab and benralizumab had similar safety profiles for patients with severe eosinophilic asthma despite their different mechanisms, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

SAN DIEGO — Among patients with COPD and heightened eosinophil levels, mepolizumab lowered annualized exacerbation rates, according to a presentation at the American Thoracic Society International Conference.

SAN DIEGO — Breath profile clusters can predict positive response to anti-IL5 or anti-IL5R alpha asthma treatment 1 month after initiation, according to an abstract presented at the American Thoracic Society International Conference.

SAN DIEGO — The relative expressions of three genes associated with the airway predicted mepolizumab response among urban children with asthma, according to a study presented at the American Thoracic Society International Conference.